Close Menu

NEW YORK – A team of researchers at the University of Bristol in the UK has been awarded £500,000 ($640,000) to support the development of a new blood-based test for the early diagnosis of brain cancer. The researchers envisage deploying a point-of-care assay based on a fluorescent nanophotonics platform.

Cancer Research UK is funding the project, which is slated to run through 2024 and will commence next month.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.